suxamethonium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
quaternary ammonium compounds	2489	306-40-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: suxamethonium chloride succinylcholine suxamethonium dicholine succinate succinic acid dicholine diester succinocholine succinoylcholine succinylbischoline succinylcholine chloride	A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for. Molecular weight: 290.40 Formula: C14H30N2O4 CLOGP: -6.87 LIPINSKI: 0 HAC: 6 HDO: 0 TPSA: 52.60 ALOGS: -5.68 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

suxamethonium chloride
succinylcholine
suxamethonium
dicholine succinate
succinic acid dicholine diester
succinocholine
succinoylcholine
succinylbischoline
succinylcholine chloride

A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.

Molecular weight: 290.40
Formula: C14H30N2O4
CLOGP: -6.87
LIPINSKI: 0
HAC: 6
HDO: 0
TPSA: 52.60
ALOGS: -5.68
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Aug. 20, 1952	FDA	SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	433.98	36.23	131	4030	20143	46661758
Cardiac arrest	186.85	36.23	110	4051	90289	46591612
Hyperthermia malignant	184.39	36.23	35	4126	714	46681187
Hypotension	181.82	36.23	156	4005	232433	46449468
Exposure during pregnancy	163.72	36.23	108	4053	108104	46573797
Diabetes insipidus	152.44	36.23	36	4125	2138	46679763
Anaphylactic reaction	134.77	36.23	74	4087	53038	46628863
Bronchospasm	134.06	36.23	51	4110	15656	46666245
Maternal exposure during pregnancy	116.64	36.23	86	4075	102463	46579438
Renal ischaemia	116.48	36.23	23	4138	580	46681321
PCO2 increased	110.44	36.23	25	4136	1229	46680672
PO2 increased	96.29	36.23	21	4140	869	46681032
Foetal death	87.78	36.23	32	4129	8711	46673190
Blood pH decreased	87.42	36.23	24	4137	2603	46679298
Oxygen saturation abnormal	86.61	36.23	24	4137	2694	46679207
Blood bicarbonate decreased	80.67	36.23	23	4138	2862	46679039
Neuromuscular block prolonged	76.81	36.23	16	4145	530	46681371
Ventricular tachycardia	76.61	36.23	35	4126	16932	46664969
Delayed recovery from anaesthesia	74.92	36.23	17	4144	844	46681057
Rhabdomyolysis	73.45	36.23	46	4115	41863	46640038
Left ventricular dysfunction	72.27	36.23	29	4132	10226	46671675
Bradycardia	71.66	36.23	54	4107	66244	46615657
Foetal exposure during pregnancy	67.46	36.23	39	4122	30708	46651193
Pulseless electrical activity	67.39	36.23	25	4136	7142	46674759
Apnoea	59.59	36.23	23	4138	7316	46674585
Status epilepticus	57.38	36.23	27	4134	13952	46667949
Drug interaction	54.47	36.23	78	4083	203016	46478885
Anaesthetic complication	53.12	36.23	15	4146	1802	46680099
Renal impairment	51.89	36.23	47	4114	74325	46607576
Premature baby	50.75	36.23	27	4134	18085	46663816
Blood magnesium decreased	50.63	36.23	23	4138	10969	46670932
Electroencephalogram abnormal	50.15	36.23	17	4144	3737	46678164
Patent ductus arteriosus	49.67	36.23	17	4144	3845	46678056
Kounis syndrome	49.51	36.23	13	4148	1189	46680712
Encephalopathy	46.91	36.23	32	4129	33557	46648344
Ventricular fibrillation	46.55	36.23	22	4139	11474	46670427
Clonus	44.94	36.23	16	4145	4064	46677837
Hyperkalaemia	43.34	36.23	36	4125	50673	46631228
Blood calcium decreased	42.88	36.23	23	4138	15650	46666251
Maternal exposure during delivery	39.32	36.23	10	4151	806	46681095
Diarrhoea	38.71	36.23	3	4158	559599	46122302
Seizure	38.54	36.23	51	4110	123003	46558898
Unresponsive to stimuli	36.48	36.23	27	4134	32147	46649754

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	335.27	34.29	68	2925	1766	29947719
Anaphylactic shock	238.06	34.29	78	2915	13915	29935570
Anaphylactic reaction	146.12	34.29	66	2927	27916	29921569
Serotonin syndrome	139.17	34.29	56	2937	17835	29931650
Cardiac arrest	104.66	34.29	81	2912	92769	29856716
Bronchospasm	75.63	34.29	31	2962	10307	29939178
Anaesthetic complication	69.34	34.29	17	2976	1052	29948433
Rhabdomyolysis	68.30	34.29	54	2939	63526	29885959
Procedural hypotension	64.96	34.29	16	2977	1009	29948476
Seizure like phenomena	58.14	34.29	13	2980	537	29948948
Pseudocholinesterase deficiency	54.87	34.29	8	2985	23	29949462
Neuromuscular block prolonged	51.74	34.29	11	2982	358	29949127
Metabolic acidosis	51.69	34.29	37	2956	37424	29912061
Hypotension	51.39	34.29	80	2913	200485	29749000
Ventricular tachycardia	51.04	34.29	31	2962	23831	29925654
Blood creatine phosphokinase increased	48.66	34.29	38	2955	43810	29905675
Muscle rigidity	46.55	34.29	22	2971	10239	29939246
Apnoea	43.15	34.29	18	2975	6240	29943245
Pseudomonal sepsis	40.14	34.29	14	2979	2986	29946499
Methaemoglobinaemia	38.60	34.29	13	2980	2497	29946988
Drug interaction	34.51	34.29	67	2926	199501	29749984

Pharmacologic Action:

Source	Code	Description
ATC	M03AB01	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Choline derivatives
FDA EPC	N0000175719	Depolarizing Neuromuscular Blocker
FDA PE	N0000175733	Neuromuscular Depolarizing Blockade
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D009466	Neuromuscular Blocking Agents
MeSH PA	D009467	Neuromuscular Depolarizing Agents
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:51371	muscle relaxants
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Muscle relaxation, function	indication	11977004
General anesthesia	indication	50697003
Skeletal Muscle Relaxation for Endotracheal Intubation	indication
Ocular hypertension	contraindication	4210003	DOID:9282
Hypocalcemia	contraindication	5291005
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Glaucoma	contraindication	23986001	DOID:1686
Infectious disease	contraindication	40733004
Myxedema	contraindication	43153006	DOID:11634
Hypokalemia	contraindication	43339004
Burn injury	contraindication	48333001
Bradycardia	contraindication	48867003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Muscular dystrophy	contraindication	73297009	DOID:9884
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Third degree burn injury	contraindication	80247002
Spinal cord injury	contraindication	90584004
Myasthenia gravis	contraindication	91637004	DOID:437
Fracture of bone	contraindication	125605004
Disorder of muscle	contraindication	129565002	DOID:423
Spasticity	contraindication	221360009
Rhabdomyolysis	contraindication	240131006
Anemia	contraindication	271737000	DOID:2355
Injury of eye region	contraindication	282752000
Deficiency of cholinesterase	contraindication	360607009
At risk for aspiration	contraindication	371736008
Primary malignant neoplasm	contraindication	372087000
Surgical procedure on eye proper	contraindication	373353005
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Malignant hyperthermia	contraindication	405501007
Cardiac arrest	contraindication	410429000	DOID:0060319
Traumatic injury	contraindication	417746004
Cardiac Decompensation	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Muscle-type nicotinic acetylcholine receptor	Ion channel	P02708 P07510 P11230 Q04844 Q07001	ACHA_HUMAN ACHB_HUMAN ACHD_HUMAN ACHE_HUMAN ACHG_HUMAN	AGONIST				CHEMBL	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		Ki	4.68		CHEMBL

External reference:

ID	Source
4017730	VUID
N0000178917	NUI
D00766	KEGG_DRUG
71-27-2	SECONDARY_CAS_RN
4017730	VANDF
4019935	VANDF
C0038627	UMLSCUI
CHEBI:45652	CHEBI
SCK	PDB_CHEM_ID
CHEMBL703	ChEMBL_ID
CHEMBL983	ChEMBL_ID
DB00202	DRUGBANK_ID
D013390	MESH_DESCRIPTOR_UI
5314	PUBCHEM_CID
4004	IUPHAR_LIGAND_ID
26	INN_ID
J2R869A8YF	UNII
10154	RXNORM
1940	MMSL
5517	MMSL
d00376	MMSL
001676	NDDF
005590	NDDF
372724004	SNOMEDCT_US
3822002	SNOMEDCT_US
58907007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	13 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	13 sections
QUELICIN	Human prescription drug label	1	0409-6629	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	13 sections
QUELICIN	Human prescription drug label	1	0409-6970	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	13 sections
QUELICIN	Human prescription drug label	1	0409-6970	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	NDA	13 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3009	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	23 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3411	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Anectine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-9053	INJECTION, SOLUTION	20 mg	INTRAVENOUS	NDA	20 sections
Succinylcholine Chloride	Human Prescription Drug Label	1	14445-407	INJECTION	20 mg	INTRAVENOUS	ANDA	22 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-104	INJECTION	20 mg	INTRAVENOUS	ANDA	21 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-493	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	13 sections
Succinylcholine Chloride	Human Prescription Drug Label	1	31722-981	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	21 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-371	INJECTION	200 mg	INTRAMUSCULAR	ANDA	21 sections
Succinylcholine	HUMAN PRESCRIPTION DRUG LABEL	1	43598-666	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	20 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	49396-0152	INJECTION	200 mg	PARENTERAL	ANDA	2 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1353	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	NDA	13 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1525	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	12 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1526	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	13 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51991-964	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	22 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-097	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	12 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-964	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	13 sections
Succinylcholine Chloride	Human prescription drug label	1	52817-734	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	22 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	54879-037	INJECTION	20 mg	INTRAVENOUS	ANDA	22 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	63323-943	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	22 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	66794-232	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	13 sections
SUCCINYLCHOLINE CHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	68001-448	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	20 sections
Succinylcholine Chloride	Human Prescription Drug Label	1	68083-450	INJECTION, SOLUTION	20 mg	INTRAVENOUS	ANDA	12 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	69918-700	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	20 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	69918-700	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	20 sections
Succinylcholine Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	70069-301	INJECTION, SOLUTION	20 mg	INTRAMUSCULAR	ANDA	12 sections